drugset
drugset / Trial / NCT00522236

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

NCT00522236 ↗

Phase 2 Completed 56 enrolled Novartis Vaccines
Non-randomizedSingle-groupOpen-labelPrevention

Summary

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over

Timeline

Start
2007-06
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject FLUAD Vaccine 0.5 ml Intramuscular

Indications

influenza